Indications for: BYETTA
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Limitations of Use:
Not for treating type 1 diabetes. Not studied in patients with a history of pancreatitis. Should not be used with other exenatide-containing products.
Give by SC inj into thigh, abdomen, or upper arm within 60mins before AM and PM meals (or before the 2 main meals of the day, approx. ≥6hrs apart). Initially 5mcg twice daily; may increase to 10mcg twice daily after 1 month. Moderate renal impairment (CrCl 30–50mL/min): caution when initiating or escalating doses from 5mcg to 10mcg.
History of drug-induced immune-mediated thrombocytopenia from exenatide products.
Do not reuse or share pens between patients, even if the needle is changed. History of pancreatitis; consider other antidiabetic therapies. Monitor for pancreatitis, drug-induced thrombocytopenia; discontinue if suspected; do not restart if confirmed. Acute gallbladder disease (eg, cholelithiasis, cholecystitis). Perform gallbladder studies and clinical follow-up if cholelithiasis is suspected. History of anaphylaxis or angioedema with another GLP-1 agonist; monitor closely. Severe GI disorders, renal impairment (CrCl <30mL/min), ESRD: not recommended. Renal transplantation. Elderly. Pregnancy. Nursing mothers.
Glucagon-like peptide-1 (GLP-1) receptor agonist.
Increased risk of hypoglycemia with concomitant sulfonylurea, insulin, or other insulin secretagogues; may need lower dose of these. May delay absorption of oral drugs (take these ≥1hr before exenatide). Monitor warfarin.
GI upset, hypoglycemia, feeling jittery, dizziness, headache, dyspepsia, constipation, asthenia; antibody formation (glycemic response may be attenuated), pancreatitis (may be fatal), hypersensitivity reactions (discontinue if occur), acute renal injury.
Generic Drug Availability:
Prefilled pen (1.2mL, 2.4mL)—1 (60 doses)